A hypothesis-generating search for new genetic breast cancer syndromes - a national study in 803 Swedish families

Hereditary Cancer in Clinical Practice

Lennart Iselius²  Camilla Gardman⁴  Richard Rosenquist⁷  Zakaria Einbeigi³  Henrik Grönberg⁸  The South Swedish Oncogenetic Study Group¹  Annika Lindblom⁵  Anna von Wachenfeldt⁶ 

[1] Departments of Clinical Genetics and Oncology, University Hospital Lund, Lund, Sweden;Department of Surgery, Karolinska University Hospital, Stockholm, Sweden;Department of Oncology, Sahlgrenska Academy at Goteborg University, Goteborg, Sweden;Department of Clinical Genetics, Linkoping University Hospital, Linkoping, Sweden;Department of Molecular Medicine and Surgery, CMM, Karolinska University Hospital, Stockholm, Sweden;Department of Oncology, Karolinska University Hospital, Sodersjukhuset, Karolinska Institute, Stockholm, Sweden;Department of Genetic and Pathology, Uppsala University, Uppsala, Sweden;Oncologic Center, Umeå University Hospital, Umeå, Sweden

关键词: genetics;    syndromes;    family history;    endometrial cancer;    breast cancer;   

Others  :  1183592
DOI  :  10.1186/1897-4287-5-1-17

【 摘 要 】

Among Swedish families with an inherited predisposition for breast cancer, less than one third segregate mutations in genes known to be associated with an increased risk of breast cancer in combination with other types of tumours. In a search for new putative familial breast cancer syndromes we studied Swedish families undergoing genetic counselling during 1992-2000.

Four thousand families from counselling clinics in Sweden were eligible for study. Families with breast cancer only were excluded, as were families with mutations in genes already known to be associated with malignant diseases. We identified 803 families with two or more cases of breast cancer and at least one other type of cancer. The observed proportion of different types of non-breast cancer was compared with the percentage distribution of non-breast cancer tumours in Sweden in 1958 and 1999.

We found tumours in the colon, ovary, endometrium, pancreas and liver, as well as leukaemia in a significantly larger proportion of the study population than in the general population in both years. These tumours were also seen among families where several members had one additional tumour, suggesting that malignancies at these sites, in combination with breast tumours, could constitute genetic syndromes. Endometrial carcinoma has not previously been described in the context of breast cancer syndromes and the excess of malignancies at this site could not be explained by secondary tumours. Thus, we suggest that endometrial carcinoma and breast cancer constitute a new breast cancer syndrome. Further investigation is warranted to categorize phenotypes of both breast and endometrial tumours in this subgroup.

   

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Cancer incidence in Sweden 1999: Swedish National Board of Health and Welfare.
• [2]Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Koskenvuo M, Pukkala E, Skytthe A, Hemminki K: Environmental and heritable factors in the causation of cancer - analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000, 343:78-85.
• [3]Claus EB, Risch N, Thompson WD: Genetic analysis of breast cancer in the cancer and steroid hormone study. Am J Hum Genet 1991, 48:232-242.
• [4]Claus EB, Risch NJ, Thompson WD: Age at onset as an indicator of familialrisk of breast cancer. Am J Epidemiol 1990, 131:961-972.
• [5]King MC, Go RC, Lynch HT Elston RC, Terasaki PI, Petrakis NL, Rodgers GC, Lattanzio D, Bailey-Wilson J: Genetic epidemiology of breast cancer and associated cancers in high-risk families. II. Linkage analysis. J Natl Cancer Inst 1983, 71:463-467.
• [6]Li FP, Fraumeni JF Jr: Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med 1969, 71:747-752.
• [7]Nichols KE, Malkin D, Garber JE, Fraumeni JF Jr, Li FP: Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol Biomarker Prev 2001, 10:83-87.
• [8]Zelada-Hedman M, Borresen-Dale AL, Claro A, Chen J, Skoog L, Lindblom A: Screening for TP53 mutations in patients and tumours from 109 Swedish breast cancer families. Br J Cancer 1997, 75:1201-1204.
• [9]Bell DW, Varley JM, Szydlo TE, Kang DH, Wahrer DC, Shannon KE, Lubratovich M, Verselis SJ, Isselbacher KJ, Fraumeni JF, Birch JM, Li FP, Garber JE, Haber DA: Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 1999, 286:2528-2531.
• [10]CHEK2 Breast Cancer Case-Control Consortium: CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. Am J Hum Genet 2004, 74:1175-1182.
• [11]Liaw D, Marsh DJ, Li J, Dahia PL, Wang SI, Zheng Z, Bose S, Call KM, Tsou HC, Peacocke M, Eng C, Parsons R: Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 1997, 16:64-67.
• [12]Chen J, Lindblom P, Lindblom A: A study of the PTEN/MMAC1 gene in 136 breast cancer families. Hum Genet 1998, 102:124-125.
• [13]Keller G, Vogelsang H, Becker I, Hutter J, Ott K, Candidus S, Grundei T, Becker KF, Mueller J, Siewert JR, Hofler H: Diffuse type gastric and lobular breast carcinoma in a familial gastric cancer patient with an E-cadherin germline mutation. Am J Pathol 1999, 155:337-342.
• [14]Salahshor S, Haixin L, Huo H, Kristensen VN, Loman N, Sjoberg-Margolin S, Borg A, Borresen-Dale AL, Vorechovsky I, Lindblom A: Low frequency of E-cadherin alterations in familial breast cancer. Breast Cancer Res 2001, 3:199-207. BioMed Central Full Text
• [15]Borg A, Sandberg T, Nilsson K, Johannsson O, Klinker M, Masback A, Westerdahl J, Olsson H, Ingvar C: High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. J Natl Cancer Inst 2000, 92:1260-1266.
• [16]Athma P, Rappaport R, Swift M: Molecular genotyping shows that ataxia-telangiectasia heterozygotes are predisposed to breast cancer. Cancer Genet Cytogenet 1996, 92:130-134.
• [17]Chen J, Birkholtz GG, Lindblom P, Rubio C, Lindblom A: The role of ataxia-telangiectasia heterozygotes in familial breast cancer. Cancer Res 1998, 58:1376-1379.
• [18]Chenevix-Trench G, Spurdle AB, Gatei M, Kelly H, Marsh A, Chen X, Donn K, Cummings M, Nyholt D, Jenkins MA, Scott C, Pupo GM, Dork T, Bendix R, Kirk J, Tucker K, McCredie MR, Hopper JL, Sambrook J, Mann GJ, Khanna KK: Dominant negative ATM mutations in breast cancer families. J Natl Cancer Inst 2002, 94:205-215.
• [19]Buchholz TA, Weil MM, Ashorn CL, Strom EA, Sigurdson A, Bondy M, Chakraborty R, Cox JD, McNeese MD, Story MD: A Ser49Cys variant in the ataxia telangiectasia, mutated, gene that is more common in patients with breast carcinoma compared with population controls. Cancer 2004, 100:1345-1351.
• [20]Szabo CI, Schutte M, Broeks A, Houwing-Duistermaat JJ, Thorstenson YR, Durocher F, Oldenburg RA, Wasielewski M, Odefrey F, Thompson D, Floore AN, Kraan J, Klijn JG, Ouweland AM, Wagner TM, Devilee P, Simard J, van't Veer LJ, Goldgar DE, Meijers-Heijboer H: Are ATM mutations 7271T->G and IVS10-6T->G really high-risk breast cancer-susceptibility alleles. Cancer Res 2004, 64:840-843.
• [21]Bernstein JL, Bernstein L, Thompson WD, Lynch CF, Malone KE, Teitelbaum SL, Olsen JH, Anton-Culver H, Boice JD, Rosenstein BS, Borresen-Dale AL, Gatti RA, Concannon P, Haile RW: WECARE Study Collaborative Group. ATM variants 7271T>G and IVS10-6T>G among women with unilateral and bilateral breast cancer. Br J Cancer 2003, 89:1513-1516.
• [22]Henriksson K, Olsson H, Kristoffersson U: The need for oncogenetic counselling. Ten years' experience of a regional oncogenetic clinic. Acta Oncol 2004, 43:637-649.
• [23]Einbeigi Z, Bergman A, Kindblom LG, Martinsson T, Meis-Kindblom JM, Nordling M, Suurkula M, Wahlstrom J, Wallgren A, Karlsson P: A founder mutation of the BRCA1 gene in Western Sweden associated with a high incidence of breast and ovarian cancer. Eur J Cancer 2001, 37:1904-1909.
• [24]Arver B, Claro A, Langerod A, Borresen-Dale AL, Lindblom A: BRCA1 screening in patients with a family history of breast or ovarian cancer. Genet Test 1999, 3:223-226.
• [25]Goshen R, Chu W, Elit L, Pal T, Hakimi J, Ackerman I, Fyles A, Mitchell M, Narod SA: Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome? Gynecol Oncol 2000, 79:477-481.
• [26]Lorenzo Bermejo J, Hemminki K: Familial association of histology specific breast cancers with cancers at other sites. Int J Cancer 2004, 109:430-435.